Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1884 1
1885 1
1888 2
1889 3
1942 2
1948 2
1949 5
1950 3
1957 1
1958 2
1959 1
1960 2
1961 1
1963 1
1964 2
1965 1
1966 5
1967 1
1969 2
1970 1
1971 1
1972 2
1973 4
1974 5
1975 2
1976 3
1977 5
1978 5
1979 3
1981 2
1982 2
1983 3
1984 2
1985 1
1987 1
1988 2
1989 1
1990 2
1991 1
1992 4
1993 4
1994 3
1995 7
1996 5
1997 6
1998 7
1999 6
2000 7
2001 8
2002 4
2003 5
2004 6
2005 4
2006 6
2007 7
2008 10
2009 5
2010 7
2011 8
2012 7
2013 8
2014 5
2015 8
2016 7
2017 10
2018 5
2019 12
2020 20
2021 29
2022 22
2023 13
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

332 results

Results by year

Filters applied: . Clear all
Page 1
Conjunctivitis in dupilumab clinical trials.
Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A. Akinlade B, et al. Among authors: davis jd. Br J Dermatol. 2019 Sep;181(3):459-473. doi: 10.1111/bjd.17869. Epub 2019 May 7. Br J Dermatol. 2019. PMID: 30851191 Free PMC article.
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, Beck LA, Guttman-Yassky E, Pariser D, Blauvelt A, Weisman J, Lockshin B, Hultsch T, Zhang Q, Kamal MA, Davis JD, Akinlade B, Staudinger H, Hamilton JD, Graham NMH, Pirozzi G, Gadkari A, Eckert L, Stahl N, Yancopoulos GD, Ruddy M, Bansal A. Simpson EL, et al. Among authors: davis jd. JAMA Dermatol. 2020 Jan 1;156(1):44-56. doi: 10.1001/jamadermatol.2019.3336. JAMA Dermatol. 2020. PMID: 31693077 Free PMC article. Clinical Trial.
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, Arkwright PD, Gooderham M, Beck LA, Boguniewicz M, Sher L, Weisman J, O'Malley JT, Patel N, Hardin M, Graham NMH, Ruddy M, Sun X, Davis JD, Kamal MA, Khokhar FA, Weinreich DM, Yancopoulos GD, Beazley B, Bansal A, Shumel B. Paller AS, et al. Among authors: davis jd. J Am Acad Dermatol. 2020 Nov;83(5):1282-1293. doi: 10.1016/j.jaad.2020.06.054. Epub 2020 Jun 20. J Am Acad Dermatol. 2020. PMID: 32574587 Free article. Clinical Trial.
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S, Kawashima M, Ferrándiz C, Smith CH, Beck LA, Chan KC, Chen Z, Akinlade B, Hultsch T, Staudinger H, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Ardeleanu M. Worm M, et al. Among authors: davis jd. JAMA Dermatol. 2020 Feb 1;156(2):131-143. doi: 10.1001/jamadermatol.2019.3617. JAMA Dermatol. 2020. PMID: 31876900 Free PMC article. Clinical Trial.
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects.
Li Z, Radin A, Li M, Hamilton JD, Kajiwara M, Davis JD, Takahashi Y, Hasegawa S, Ming JE, DiCioccio AT, Li Y, Kovalenko P, Lu Q, Ortemann-Renon C, Ardeleanu M, Swanson BN. Li Z, et al. Among authors: davis jd. Clin Pharmacol Drug Dev. 2020 Aug;9(6):742-755. doi: 10.1002/cpdd.798. Epub 2020 Apr 29. Clin Pharmacol Drug Dev. 2020. PMID: 32348036 Free PMC article.
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M. Deleuran M, et al. Among authors: davis jd. J Am Acad Dermatol. 2020 Feb;82(2):377-388. doi: 10.1016/j.jaad.2019.07.074. Epub 2019 Jul 30. J Am Acad Dermatol. 2020. PMID: 31374300 Free article. Clinical Trial.
A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy.
Paller AS, Siegfried EC, Simpson EL, Cork MJ, Lockshin B, Kosloski MP, Kamal MA, Davis JD, Sun X, Pirozzi G, Graham NMH, Gadkari A, Eckert L, Ruddy M, Bansal A. Paller AS, et al. Among authors: davis jd. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):464-475. doi: 10.1111/jdv.16928. Epub 2020 Nov 8. J Eur Acad Dermatol Venereol. 2021. PMID: 32893393 Free PMC article. Clinical Trial.
Dynamical systems approaches to personalized medicine.
Davis JD, Kumbale CM, Zhang Q, Voit EO. Davis JD, et al. Curr Opin Biotechnol. 2019 Aug;58:168-174. doi: 10.1016/j.copbio.2019.03.005. Epub 2019 Apr 9. Curr Opin Biotechnol. 2019. PMID: 30978644 Free PMC article. Review.
Is it time to revisit ICD indications?
Yehya A, Davis JD, Sauer AJ, Ibrahim NE. Yehya A, et al. Among authors: davis jd. Heart Fail Rev. 2022 Nov;27(6):2177-2179. doi: 10.1007/s10741-022-10215-z. Epub 2022 Jan 26. Heart Fail Rev. 2022. PMID: 35080736 Review. No abstract available.
332 results